RGNX
Regenxbio Inc (RGNX)
Healthcare • NASDAQ • $10.55+1.25%
- Symbol
- RGNX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $10.55
- Daily Change
- +1.25%
- Market Cap
- $544.56M
- Trailing P/E
- N/A
- Forward P/E
- -4.80
- 52W High
- $16.19
- 52W Low
- $7.35
- Analyst Target
- $27.82
- Dividend Yield
- N/A
- Beta
- 1.12
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Furth…
Company websiteResearch RGNX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.